The Cost-effectiveness of Risedronate Treatment in Japanese Women with Osteoporosis

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2007 Dec 21

PMID 18095061

Citations 10

Authors

Hansheng Ding

Nobuo Koinuma

Matt Stevenson

Michiya Ito

Yasutake Monma

Affiliations

Soon will be listed here.

Abstract

We constructed a mathematical model for assessing the cost-effectiveness of providing BMD (bone mineral density) scans to Japanese women aged 55 years and over and treating, with risedronate, those that are shown to be osteoporotic. Fracture rates, cost data, utility values, and the increased risks of fractures associated with T-score and vertebral fracture history were taken from published literature. We estimated the cost of fractures avoided due to risedronate treatment, allowing the net changes in cost, incorporating both intervention and fracture costs to be calculated. The QALYs (quality adjusted life years) gained through treatment were calculated enabling cost per QALY ratios to be presented. Further analyses were undertaken assuming treatment was reserved for older women and/or those who had sustained a vertebral fracture in the previous 2 years. Cost per QALY values were inversely related to absolute risk of fracture. Assuming a cost per QALY value threshold of US dollars 100,000, we concluded that providing BMD scans to women aged 70 years and over who had sustained a vertebral fracture in the previous 2 years and treating those that were osteoporotic was cost-effective. However, providing BMD scans for women without a vertebral fracture in the previous 2 years was not cost-effective, even in women aged 85 years and older.

Citing Articles

Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal.

Azharuddin M, Adil M, Khan R, Ghosh P, Kapur P, Sharma M Osteoporos Sarcopenia. 2020; 6(2):39-52.

PMID: 32715093 PMC: 7374246. DOI: 10.1016/j.afos.2020.05.006.

Osteoporosis in East Asia: Current issues in assessment and management.

Cheung E, Tan K, Cheung C, Kung A Osteoporos Sarcopenia. 2019; 2(3):118-133.

PMID: 30775478 PMC: 6372753. DOI: 10.1016/j.afos.2016.07.001.

Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.

Su Y, Lai F, Yip B, Leung J, Kwok T Osteoporos Int. 2018; 29(8):1793-1805.

PMID: 29774400 DOI: 10.1007/s00198-018-4543-4.

Treatment costs and cost drivers among osteoporotic fracture patients in Japan: a retrospective database analysis.

Taguchi Y, Inoue Y, Kido T, Arai N Arch Osteoporos. 2018; 13(1):45.

PMID: 29696390 PMC: 5918517. DOI: 10.1007/s11657-018-0456-2.

Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori?.

Asaoka D, Nagahara A, Shimada Y, Matsumoto K, Ueyama H, Matsumoto K Ther Clin Risk Manag. 2015; 11:381-91.

PMID: 25834453 PMC: 4358368. DOI: 10.2147/TCRM.S80647.

References

Whang W, Sisk J, Heitjan D, Moskowitz A . Probabilistic sensitivity analysis in cost-effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderly. Int J Technol Assess Health Care. 2000; 15(3):563-72. View

Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M . Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001; 19(6):331-7. DOI: 10.1007/s007740170001. View

Krappweis J, Rentsch A, Schwarz U, Krobot K, Kirch W . Outpatient costs of osteoporosis in a national health insurance population. Clin Ther. 2000; 21(11):2001-14. DOI: 10.1016/S0149-2918(00)86745-4. View

Lindsay R . The burden of osteoporosis: cost. Am J Med. 1995; 98(2A):9S-11S. DOI: 10.1016/s0002-9343(05)80038-5. View

Sato Y, Iwamoto J, Kanoko T, Satoh K . Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med. 2005; 165(15):1743-8. DOI: 10.1001/archinte.165.15.1743. View

Rahman M, Sekimoto M, Takamatsu I, Hira K, Shimbo T, Toyoshima K . Economic evaluation of universal BCG vaccination of Japanese infants. Int J Epidemiol. 2001; 30(2):380-5. DOI: 10.1093/ije/30.2.380. View

Cummings S, Rubin S, Black D . The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop Relat Res. 1990; (252):163-6. View

Melton 3rd L . Hip fractures: a worldwide problem today and tomorrow. Bone. 1993; 14 Suppl 1:S1-8. DOI: 10.1016/8756-3282(93)90341-7. View

Eastell R, Boyle I, Compston J, Cooper C, Fogelman I, Francis R . Management of male osteoporosis: report of the UK Consensus Group. QJM. 1998; 91(2):71-92. DOI: 10.1093/qjmed/91.2.71. View

10.

Kishimoto H . [Change in the definition of osteoporosis especially on bone quality]. Clin Calcium. 2005; 15(5):736-40. DOI: CliCa0505736740. View

11.

Kanis J, Gluer C . An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int. 2000; 11(3):192-202. DOI: 10.1007/s001980050281. View

12.

Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T . A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab. 2004; 22(5):469-78. DOI: 10.1007/s00774-004-0509-z. View

13.

Weinstein M, Stason W . Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977; 296(13):716-21. DOI: 10.1056/NEJM197703312961304. View

14.

. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993; 94(6):646-50. DOI: 10.1016/0002-9343(93)90218-e. View

15.

Reginster J, Minne H, Sorensen O, Hooper M, Roux C, Brandi M . Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11(1):83-91. DOI: 10.1007/s001980050010. View

16.

. Who are candidates for prevention and treatment for osteoporosis?. Osteoporos Int. 1997; 7(1):1-6. DOI: 10.1007/BF01623453. View

17.

Schuit S, van der Klift M, Weel A, de Laet C, Burger H, Seeman E . Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004; 34(1):195-202. DOI: 10.1016/j.bone.2003.10.001. View

18.

Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, MINAGUCHI H . A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int. 2003; 14(3):225-34. DOI: 10.1007/s00198-002-1369-9. View

19.

Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A . Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab. 2006; 24(2):105-13. DOI: 10.1007/s00774-005-0655-y. View

20.

Klotzbuecher C, Ross P, Landsman P, Abbott 3rd T, Berger M . Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15(4):721-39. DOI: 10.1359/jbmr.2000.15.4.721. View